SCOTT M ROCKLAGE

CIK 1219014 · last filed 2024-03-15

SCOTT M ROCKLAGE is a corporate insider who has filed 29 SEC Form 4 insider transactions across 14 companies since 2013. Across all open-market trades the lifetime net is +$11.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $66.5M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$66.54M

Companies

14

Total Filings

29

Lifetime Open-Market Net

$11.89M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
RLYB 10%+ Owner 1,251,755 $15.92 $19.93M -$19.72M 2 2023-03-09
Pear Therapeutics, Inc. (PEARW) Delisted 10%+ Owner 537,406 $0.01 $3.2K -$2.31M 1 2022-11-15
Akouos, Inc. (AKUS) Delisted 10%+ Owner 3,153,331 $13.29 $41.91M -$50.76M 1 2020-12-31
APRE Director 75,965 $0.69 $52.1K -$20.01M 5 2020-07-01
CABA 10%+ Owner 3,214,721 $3.01 $9.68M $35.00M 1 2019-10-31
IDYA 10%+ Owner 84,420 $28.98 $2.45M $37.50M 1 2019-05-28
ARVN 10%+ Owner 4,512,136 $7.58 $34.20M -$30.68M 1 2019-04-01
Cidara Therapeutics, Inc. (CDTX) Delisted Director $221.38 $0 4 2018-06-15
scPharmaceuticals Inc. (SCPH) Delisted 10%+ Owner 103,945 $5.67 $589.4K $55.00M 1 2017-11-21
PULM Director 168,873 $1.40 $236.4K $266.8K 4 2016-02-25
EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted Director 2,549,211 $2.00M 2 2015-06-08
VIVEVE MEDICAL, INC. (TCON) Delisted 10%+ Owner 7,310,231 $0.03 $235.4K $1.50M 1 2015-05-29
Achaogen, Inc. (AKAO) Delisted Director $0 1 2014-03-13
Relypsa Inc (RLYP) Delisted Director 2,258,376 $4.10M 2 2013-11-20

Recent Filings

29 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2024-03-15 Buy (P) +3,600,000 $36.00M
2024-02-02 Buy (P) +41,648,592 $96.21M
2023-03-09 RLYB Sell (S) −400,000 -$3.28M EDGAR
2022-11-15 Pear Therapeutics, Inc. (PEARW) Delisted Sell (S) −842,248 -$2.31M EDGAR
2022-02-10 RLYB Sell (S) −1,260,000 -$16.44M EDGAR
2020-12-31 Akouos, Inc. (AKUS) Delisted Sell (S) −2,820,000 -$50.76M EDGAR
2020-07-01 APRE Grant (A) $0 EDGAR
2020-06-18 APRE Sell (S) −120,164 -$4.00M EDGAR
2020-06-15 APRE Sell (S) −245,000 -$7.04M EDGAR
2020-05-21 APRE Sell (S) −255,000 -$8.96M EDGAR
Showing 110 of 29
Page 1 of 3
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.